Global Central Nervous System Therapeutics Market Size Study, By Disease Outlook (Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer, Others) and Regional Forecasts 2022-2032

Description

Global Central Nervous System Therapeutics Market is valued at approximately USD 143.95 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 7.5% over the forecast period 2024-2032. Central Nervous System (CNS) Therapeutics refers to a range of medications, treatments, and therapies designed to diagnose, manage, and treat disorders and diseases affecting the central nervous system. The CNS, which includes the brain and spinal cord, controls most of the body's functions, including thought processes, motor skills, and sensory perception. CNS therapeutics encompass a variety of approaches, such as pharmaceuticals, biologics, gene therapies, and medical devices, targeting conditions like Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, depression, schizophrenia, and other neurological or psychiatric disorders. The aim is to alleviate symptoms, slow disease progression, or restore normal CNS function.

Advancements in the diagnostics and therapeutics of CNS diseases have revolutionized treatment approaches globally. Rising awareness regarding CNS disorders, coupled with the growing prevalence of conditions such as Alzheimer's, multiple sclerosis, epilepsy, and Parkinson's disease, continues to drive demand for effective therapeutic options. According to the World Health Organization (WHO), more than one billion people are affected by CNS disorders worldwide, further underscoring the substantial unmet medical need in this market. Moreover, the increasing awareness of mental health and neurodegenerative diseases, combined with government initiatives, is further supporting the growth of the CNS therapeutics market. However, the regulatory hurdles and high cost of different therapies are challenging the market growth throughout the forecast period of 2024-2032.

Regionally, North America remains the largest market for CNS therapeutics, driven by the presence of key players, advanced healthcare infrastructure, and awareness campaigns that focus on CNS disease diagnosis and treatment. Asia Pacific, however, is poised to experience the highest growth rate, supported by improvements in healthcare infrastructure, increased awareness, and a large patient base with unmet medical needs in countries such as China and India.

Major Market Players Included in This Report:

Biogen
Otsuka Pharmaceutical Co., Ltd.
Eli Lilly and Company
Johnson & Johnson Services, Inc.
Pfizer, Inc.
Novartis International AG
Roche Holding AG
Teva Pharmaceutical Industries Ltd.
Merck & Co., Inc.
Bristol-Myers Squibb Company
AbbVie Inc.
Sanofi S.A.
Amgen Inc.
AstraZeneca PLC
GlaxoSmithKline plc (GSK)

The detailed segments and sub-segment of the market are explained below:

By Disease Outlook:

Neurovascular Diseases
CNS Trauma
Mental Health
Neurodegenerative Diseases
Infectious Diseases
CNS Cancer
Others

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional-level analysis for each market segment.
Detailed analysis of geographical landscape with country-level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approaches.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Central Nervous System Therapeutics Market Executive Summary

1.1 Global CNS Therapeutics Market Size & Forecast (2022-2032)
1.2 Regional Summary
1.3 Segmental Summary
- 1.3.1 By Disease Outlook
1.4 Key Trends
1.5 Recession Impact
1.6 Analyst Recommendations & Conclusion

Chapter 2. Global Central Nervous System Therapeutics Market Definition and Research Assumptions

2.1 Research Objective
2.2 Market Definition
2.3 Research Assumptions
- 2.3.1 Inclusion & Exclusion
- 2.3.2 Limitations
- 2.3.3 Supply Side Analysis
  - 2.3.3.1 Availability
  - 2.3.3.2 Infrastructure
  - 2.3.3.3 Regulatory Environment
  - 2.3.3.4 Market Competition
  - 2.3.3.5 Economic Viability
- 2.3.4 Demand Side Analysis
  - 2.3.4.1 Regulatory Frameworks
  - 2.3.4.2 Technological Advancements
  - 2.3.4.3 Environmental Considerations
  - 2.3.4.4 Consumer Awareness & Acceptance
2.4 Estimation Methodology
2.5 Years Considered for the Study
2.6 Currency Conversion Rates

Chapter 3. Global Central Nervous System Therapeutics Market Dynamics

3.1 Market Drivers
- 3.1.1 Growing Prevalence of CNS Disorders
- 3.1.2 Rising Approvals of Generic Drugs
- 3.1.3 Technological Advancements in Drug-Delivery Systems
3.2 Market Challenges
- 3.2.1 Regulatory Hurdles
- 3.2.2 High Cost of Different Therapies
3.3 Market Opportunities
- 3.3.1 Expansion of Healthcare Infrastructure in Emerging Markets
- 3.3.2 Increasing Awareness of Mental Health

Chapter 4. Global Central Nervous System Therapeutics Market Industry Analysis

4.1 Porter's Five Forces Model
- 4.1.1 Bargaining Power of Suppliers
- 4.1.2 Bargaining Power of Buyers
- 4.1.3 Threat of New Entrants
- 4.1.4 Threat of Substitutes
- 4.1.5 Competitive Rivalry
4.2 PESTEL Analysis
- 4.2.1 Political
- 4.2.2 Economic
- 4.2.3 Social
- 4.2.4 Technological
- 4.2.5 Environmental
- 4.2.6 Legal
4.3 Top Investment Opportunities
4.4 Top Winning Strategies
4.5 Disruptive Trends
4.6 Industry Expert Perspective
4.7 Analyst Recommendations & Conclusion

Chapter 5. Global Central Nervous System Therapeutics Market Size & Forecasts by Disease Outlook (2022-2032)

5.1 Segment Dashboard
5.2 Global CNS Therapeutics Market: Disease Outlook Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1 Neurovascular Diseases
- 5.2.2 CNS Trauma
- 5.2.3 Mental Health
- 5.2.4 Neurodegenerative Diseases
- 5.2.5 Infectious Diseases
- 5.2.6 CNS Cancer
- 5.2.7 Others

Chapter 6. Global Central Nervous System Therapeutics Market Size & Forecasts by Region (2022-2032)

6.1 North America CNS Therapeutics Market
- 6.1.1 U.S. CNS Therapeutics Market
  - 6.1.1.1. Distribution Channel breakdown size & forecasts, 2022-2032
- 6.1.2 Canada CNS Therapeutics Market
6.2 Europe CNS Therapeutics Market
- 6.2.1 U.K. CNS Therapeutics Market
- 6.2.2 Germany CNS Therapeutics Market
- 6.2.3 France CNS Therapeutics Market
- 6.2.4 Spain CNS Therapeutics Market
- 6.2.5 Italy CNS Therapeutics Market
- 6.2.6 Rest of Europe CNS Therapeutics Market
6.3 Asia Pacific CNS Therapeutics Market
- 6.3.1 China CNS Therapeutics Market
- 6.3.2 India CNS Therapeutics Market
- 6.3.3 Japan CNS Therapeutics Market
- 6.3.4 Australia CNS Therapeutics Market
- 6.3.5 South Korea CNS Therapeutics Market
- 6.3.6 Rest of Asia Pacific CNS Therapeutics Market
6.4 Latin America CNS Therapeutics Market
- 6.4.1 Brazil CNS Therapeutics Market
- 6.4.2 Mexico CNS Therapeutics Market
- 6.4.3 Rest of Latin America CNS Therapeutics Market
6.5 Middle East & Africa CNS Therapeutics Market
- 6.5.1 Saudi Arabia CNS Therapeutics Market
- 6.5.2 South Africa CNS Therapeutics Market
- 6.5.3 Rest of Middle East & Africa CNS Therapeutics Market

Chapter 7. Competitive Intelligence

7.1 Key Company SWOT Analysis
7.2 Top Market Strategies
7.3 Company Profiles
- 7.3.1 Biogen
  - 7.3.1.1. Key Information
  - 7.3.1.2. Overview
  - 7.3.1.3. Financial (Subject to Data Availability)
  - 7.3.1.4. Product Summary
  - 7.3.1.5. Market Strategies
- 7.3.2 Otsuka Pharmaceutical Co., Ltd.
- 7.3.3 Eli Lilly and Company
- 7.3.4 Johnson & Johnson Services, Inc.
- 7.3.5 Pfizer, Inc.
- 7.3.6 Novartis International AG
- 7.3.7 Roche Holding AG
- 7.3.8 Teva Pharmaceutical Industries Ltd.
- 7.3.9 Merck & Co., Inc.
- 7.3.10 Bristol-Myers Squibb Company
- 7.3.11 AbbVie Inc.
- 7.3.12 Sanofi S.A.
- 7.3.13 Amgen Inc.
- 7.3.14 AstraZeneca PLC
- 7.3.15 GlaxoSmithKline plc (GSK)

Chapter 8. Research Process

8.1 Research Process
- 8.1.1 Data Mining
- 8.1.2 Analysis
- 8.1.3 Market Estimation
- 8.1.4 Validation
- 8.1.5 Publishing
8.2 Research Attributes